Sitemap

B. Michael Silber, Ph.D., Scientific Advisor

B. Michael Silber, Ph.D., Scientific Advisor Dr. B. Michael Silber is a professor of Neurology, Bioengineering and Therapeutic Sciences, and Chief of Drug Discovery R& D at Institute for Neurodegenerative Diseases (IND) University of California School of Medicine. Prior to joining the faculty at UCSF and the IND, Dr. Silber held senior executive R &(…)

Yuichi Sugiyama, Ph.D., Scientific Advisor

Yuichi Sugiyama, Ph.D., Scientific Advisor Professor Sugiyama is in the Department of Molecular Pharmacokinetics at the University of Tokyo. He is the coauthor of more than 550 publications, 270 book chapters and review articles. Professor Sugiyama’s work focuses on two areas: 1) prediction of drug disposition from in vitro biochemical data. 2) Molecular pharmacokinetics of(…)

Bruno Stieger, Ph.D., Scientific Advisor

Bruno Stieger, Ph.D., Scientific Advisor Bruno Stieger, PhD is head of the research laboratory of the Department of Clinical Pharmacology and Toxicology, University Hospital, Zurich, Switzerland. He was trained as a biochemist at the Federal Institute of Technology in Zurich Switzerland and holds a PhD in biochemistry from the same institution. The Department of Clinical(…)

Pascal Druzgala, Ph.D., Co-founder & Director

Pascal Druzgala, Ph.D., Co-founder & Director Dr. Druzgala is a co-founder and has been serving on our board since July 2007. He is an experienced entrepreneur and drug design expert. He co-founded ARYx Therapeutics (NASDAQ: ARYX) where he has been serving as Senior Vice President and Chief Scientific Officer since 1997, responsible for all research(…)

Peter G. Milner, MD, FACC, Co-Founder & Director

Peter G. Milner, MD, FACC, Co-Founder & Director Dr. Milner co-founded Optivia in 2007. In 1997 Peter co-founded ARYx Therapeutics (NASDAQ:ARYX) where he served as CEO until 2005, and President from 2005 to 2010 with overall responsibility for R&D. In 1990 he co-founded CV Therapeutics (NASDAQ:CVTX), where as a member of senior management from 1992-1996(…)

Home Slide 2

Improving ADME Novel multiple-transporter models for studying drug absorption, clearance and disposition

Alan C. Mendelson, J.D., General Counsel & Secretary

Alan C. Mendelson, J.D., General Counsel and Secretary Mr. Mendelson is a partner in the Silicon Valley office of Latham & Watkins LLP, a major global law firm, and is the Co-Chair of the firm’s Life Sciences Industry Group. He joined Latham in May 2000. Mr. Mendelson received his B.A. degree from the University of(…)

Dominique Bridon, Ph.D. Executive VP & CSO

Dominique Bridon, Ph.D., Executive VP & Chief Scientific Officer Dr. Bridon holds a doctorate in organic chemistry from the University of Paris XI and completed post-doctoral research at the University of California, Berkeley. He has an engineering degree in polymer chemistry from École Nationale Supérieure d’Ingénieur of Clermont-Ferrand. Before joining Optivia, Dr. Bridon held the(…)

Yong Huang, Ph.D., Founder, President & CEO

Yong Huang, Ph.D., Founder, President & CEO Dr. Huang is an entrepreneur and innovator in the life science industry. He has over 10 years of experience in moving novel ideas to the market place. In addition to Optivia, he has founded or contributed to four life science companies. Dr. Huang is the principal investigator for(…)